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The target of rapamycin (TOR) is a highly conserved
protein kinase and a central controller of growth.
Mammalian TOR complex 2 (mTORC2) regulates
AGC kinase family members and is implicated in
various disorders, including cancer and diabetes.
Here, we investigated the upstream regulation of
mTORC2. A genetic screen in yeast and subsequent
studies in mammalian cells revealed that ribosomes,
but not protein synthesis, are required for mTORC2
signaling. ActivemTORC2was physically associated
with the ribosome, and insulin-stimulated PI3K
signaling promoted mTORC2-ribosome binding,
suggesting that ribosomes activate mTORC2 di-
rectly. Findings with melanoma and colon cancer
cells suggest that mTORC2-ribosome association is
important in oncogenic PI3K signaling. Thus,
TORC2-ribosome interaction is a likely conserved
mechanism of TORC2 activation that is physiologi-
cally relevant in both normal and cancer cells. As
ribosome content determines growth capacity of
a cell, this mechanism of TORC2 regulation ensures
that TORC2 is active only in growing cells.
INTRODUCTION
Target of rapamycin (TOR) is a central controller of cell growth
and metabolism in response to nutrients, growth factors, and
energy status. TOR is found in two structurally and functionally
distinct multiprotein complexes termed TOR complex 1
(TORC1) and TORC2 (Wullschleger et al., 2006). The TOR com-
plexes, originally described in yeast (Loewith et al., 2002), are
conserved across all eukaryotes and regulate a wide spectrum
of cellular processes that mediate cell growth (Laplante and
Sabatini, 2009; Soulard et al., 2009; Wullschleger et al., 2006;
Yang and Guan, 2007). In mammalian cells, mammalian TORC1
(mTORC1) contains mTOR, raptor, and mLST8 and is sensitive
to the immunosuppressant and anticancer drug rapamycin
(Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002). mTORC1
controls transcription, ribosome biogenesis, protein synthesis,
lipid synthesis, nutrient transport, autophagy, and other
growth-related processes. The best-characterized substrates
of mTORC1 are S6K and 4E-BP via which mTORC1 controlstranslation (Sonenberg and Hinnebusch, 2009). mTORC2
consists of mTOR, rictor, mSIN1, mLST8, and PRR5/PRR5L
(also known as protor1 and 2) and is insensitive to rapamycin,
although long-term rapamycin treatment can indirectly inhibit
mTORC2 in some cell types (Cybulski and Hall, 2009; Jacinto
et al., 2004; Sarbassov et al., 2004; Sarbassov et al., 2006;
Sparks and Guertin, 2010). mTORC2 directly phosphorylates
and activates the AGC kinases Akt (also known as PKB),
SGK1, and likely PKC (Facchinetti et al., 2008; Garcı´a-Martı´nez
and Alessi, 2008; Hresko and Mueckler, 2005; Ikenoue et al.,
2008; Jacinto and Lorberg, 2008; Sarbassov et al., 2004; Sar-
bassov et al., 2005). mTORC2 promotes cell survival via Akt
and mediates organization of the actin cytoskeleton (Cybulski
and Hall, 2009; Sparks and Guertin, 2010).
Both mTORC1 and mTORC2 are activated by growth factors,
including insulin, IGF-1, and others. Growth factors activate
mTORC1 via phosphatidylinositol 3-kinase (PI3K), PDK1, Akt,
the TSC1-TSC2 complex, and Rheb, a small guanosine triphos-
phate (GTP)-binding protein that binds and activates mTORC1
directly (Avruch et al., 2009; Manning and Cantley, 2003). In
contrast, the mechanism via which growth factors activate
mTORC2 has been elusive. Growth factors activate mTORC2
via PI3K (Frias et al., 2006; Garcı´a-Martı´nez and Alessi, 2008;
Yang et al., 2006), but signaling steps beyond PI3K are distinct
from those upstream of mTORC1 and unknown (Cybulski and
Hall, 2009; Sparks and Guertin, 2010). The nature of the
upstream regulators of TORC2 in unicellular model organisms
such as yeasts, which lack a growth factor signaling pathway,
is completely unknown (Soulard et al., 2009).
Here, we describe a genetic screen in yeast and subsequent
studies in mammalian cells that identify the ribosome as an acti-
vator of TORC2. We demonstrate that the ribosome, indepen-
dent of protein synthesis, is required for mTORC2 signaling
in vivo and mTORC2 kinase activity in vitro. Active mTORC2 is
associated with the ribosome. Insulin stimulates the association
of mTORC2 with the ribosome via PI3K signaling. Findings with
cancer cells suggest that ribosome-dependent mTORC2 activa-
tion is physiologically relevant in tumors with hyperactive PI3K
signaling.
RESULTS
A Genetic Screen Reveals that NIP7 Is Required
for TORC2 Signaling in Yeast
To identify upstream activators of TORC2, we performed
a genetic screen in the budding yeast S. cerevisiae. Furthermore,Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc. 757
we assumed that whatever activates TORC2 in yeast would also
be upstream of mTORC2 in mammals. In other words, we
assumed that growth factor signaling was grafted onto a hereto-
fore unknown ancestral input controlling TORC2 in unicellular
yeast. This reasoning was supported by the fact that growth
factor signaling was grafted onto the ancestral nutrient input in
the case of TORC1.
mTORC2 phosphorylates the hydrophobic motif in the AGC
kinase SGK1 and thereby activates SGK1. In yeast, TORC2 simi-
larly phosphorylates and activates the SGK1 ortholog YPK2. Our
genetic screen was based on the observation that overexpres-
sion of constitutively active YPK2 (YPK2D239A, hereafter referred
to as YPK2*) suppresses the lethality of a TORC2 defect
(Aronova et al., 2008; Kamada et al., 2005). Assuming that
YPK2* would also suppress lethality caused by a defect in an
upstream activator of TORC2, we performed a so-called reverse
suppressor screen to isolate yeast mutants that depend on
YPK2* for viability (Figure 1A and Experimental Procedures).
This is referred to as a reverse suppressor screen because it
starts with a suppressor mutation (YPK2*) to identify unknown
‘‘suppressee’’ mutations—the reverse order of a normal
(forward) suppressor screen. The screen was predicted to iden-
tify loss-of-function mutations in an essential upstream activator
of TORC2 or in the essential components of TORC2, including
TOR2, AVO1 (mSIN1 ortholog), and AVO3 (rictor ortholog). The
screen yielded a total of 44 independent mutants defective in
TORC2, thereby validating the screen. The 44mutants consisted
of 25, 13, and 6 tor2, avo1, and avo3 mutants, respectively. In
addition, we obtained a temperature-sensitive nip7 mutant that
we hereafter refer to as nip7-1 (Figure 1A and Figures S1A and
S1B). Sequence analysis of the nip7-1 allele identified a point
mutation that converts glycine 71 to aspartic acid. Western
blot analysis of extracts from nip7-1 cells showed that the point
mutation mildly and strongly decreased NIP7 protein levels at
permissive temperature (25C) and nonpermissive temperature
(37C), respectively (Figure S1A). YPK2*, but not wild-type
YPK2, suppressed the growth defect of the nip7-1 mutant at
semipermissive temperature (30C and 34C) (Figure S1B).
NIP7 is an essential protein required for maturation of rRNA of
the 60S ribosomal subunit (Zanchin et al., 1997). Confirming
this role of NIP7 in ribosomebiogenesis,we observed a reduction
in the amounts of the 60S subunit, the 80S ribosome, and poly-
somes, with a concomitant appearance of halfmer polysomes, in
extracts of the nip7-1 mutant grown at semipermissive temper-
ature (30C) (Figure S1C).
To examine further whether NIP7 is required for TORC2
signaling, we investigated whether the nip7-1mutant phenocop-
ied TORC2mutants. The nip7-1mutant indeed exhibited several
defects similar to those observed in temperature-sensitive
TORC2 mutants (avo3-1 and tor2-21) (Aronova et al., 2008;
Beeler et al., 1998; Facchinetti et al., 2008; Helliwell et al.,
1998; Kamada et al., 2005; Schmidt et al., 1997). First, the
nip7-1 mutant exhibited reduced signaling through the cell wall
integrity pathway, as evidenced by decreased MPK1 phosphor-
ylation and PKC1 protein levels, depolarization of the actin cyto-
skeleton, and restoration of growth in the presence of the
osmotic stabilizer sorbitol (Figure 1B and Figure S1D). Second,
the nip7-1 mutant showed impaired sphingolipid biosynthesis,758 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.including hypersensitivity to myriocin, an inhibitor of the first
step in the sphingolipid biosynthetic pathway, and restoration
of growth in the presence of Ca2+ in a csg2D background
(Figure S1E). Third, the nip7-1 mutant showed decreased
YPK2 kinase activity, as measured by an in vitro kinase assay
with immunopurified YPK2 and, as a control, kinase-dead
YPK2K373A (Figure 1C and data not shown for kinase dead).
Finally and most importantly, TORC2 kinase activity was
reduced in the nip7-1mutant, as measured by an in vitro kinase
assay with TORC2 immunopurified from wild-type cells and
nip7-1mutant cells grown at 30C (Figure 1D). The above results
strongly suggest that NIP7 is required, directly or indirectly, for
TORC2 kinase activity and signaling.
mNIP7 Is Required for mTORC2 Activity
and Ribosome Maturation in Mammals
Yeast NIP7 shares 75% identity with an uncharacterized
mammalian protein also termedNIP7 (Figure S2A).We examined
whether mammalian NIP7 (mNIP7) is required for mTORC2
signaling. mTORC2 directly phosphorylates Ser473 in the hydro-
phobicmotif of Akt and Ser422 in the hydrophobicmotif of SGK1
and thereby activates Akt and SGK1 toward substrates such as
FoxO3a (Thr32) and NDRG1 (Thr346), respectively (Garcı´a-
Martı´nez and Alessi, 2008; Sarbassov et al., 2005). mTORC2
also autophosphorylates sites in rictor (Sarbassov et al., 2004;
Jacinto et al., 2004) and is required for phosphorylation of
Thr450 in the turn motif of Akt (Facchinetti et al., 2008; Ikenoue
et al., 2008). Knockdown of mNIP7 in HeLa and HEK293 cells
strongly decreased basal and insulin-stimulated phosphoryla-
tion of Ser473 and Thr450 in Akt, Thr32 in FoxO3a, Thr346 in
NDRG1, and rictor in mTORC2 (Figure 2A, Figure S2B, and
data not shown). mNIP7 knockdown had no effect on Erk phos-
phorylation or mTORC1-dependent S6K phosphorylation (Fig-
ure 2A). These findings suggest that mNIP7 is specifically
required for mTORC2 signaling. Finally, we observed that
mNIP7 knockdown reduced (by 58%) mTORC2 kinase activity
in vitro, with no effect on mTORC2 amount or integrity (Fig-
ure 2B). These findings indicate that mNIP7 is required for
mTORC2 activity and signaling, and not for mTORC2 synthesis,
assembly, or stability. Furthermore, NIP7 is required for TORC2
signaling in both yeast and mammalian cells, suggesting
a conserved mechanism of TORC2 activation.
Is mNIP7 a 60S maturation factor like NIP7 in yeast? Knock-
down of mNIP7 reduced the amounts of the 60S ribosomal
subunit and the 80S ribosome (80S), with no effect on the
amount of the 40S subunit (Figure S2C). Knockdown ofmTORC2
component mSIN1 had no effect on the ribosome profile (Fig-
ure S2C), indicating that the effect of mNIP7 on ribosome matu-
ration was not due to a defect in signaling downstream of
mTORC2. Thus, NIP7 is conserved from yeast to human as
a 60S ribosome maturation factor and a TORC2 activator.
Ribosomes, but Not Protein Synthesis, Are Required
for mTORC2 Signaling
Does mNIP7 control mTORC2 via its role in ribosome matura-
tion? To address this question, we examined whether ribosome
content affects mTORC2 signaling. Knockdown of ribosomal
protein Rpl7 (60S subunit) reduced the amounts of the 60S
Figure 1. NIP7, Identified by a Reverse Suppressor Screen, Is Required for TORC2 Activity In Vivo and In Vitro
(A) Schematic representation of the reverse suppressor screen. A wild-type strain (JK9-3da) overexpressing constitutively active YPK2* (YPK2D239A) on an
URA3-based plasmid was mutagenized with ethyl-methanesulfonate (EMS). Mutants that could not grow on plates containing 5-FOA were chosen for further
analysis. A plasmid-borne NIP7 gene (pNIP7) was isolated by complementation of the nip7-1 mutation.
(B) nip7-1mutant exhibits depolarization of actin cytoskeleton.Wild-type (JK9-3da), avo3-1 (BAS65-2a), and nip7-1 (DS1) cells grown in YPD at 25Cwere shifted
to 37C for 6 hr. The actin cytoskeleton was stained with rhodamine-coupled phalloidin. A representative figure of three independent experiments for each strain
is shown.
(C) nip7-1 mutant shows decreased YPK2 activity. Wild-type cells (JK9-3da) (mock) and wild-type, avo3-1, or nip7-1 cells expressing plasmid-borne YPK2-HA
(pYPK2-HA) were grown in YPD at 30C. YPK2-HA was immunoprecipitated and subjected to in vitro kinase assay using cross-tide as a substrate. Substrate
phosphorylation was quantified, and the average ± standard deviation from the mean based on three independent experiments is shown. Immunoprecipitated
YPK2-HA was detected by western blotting (bottom).
(D) nip7-1 mutant shows decreased TORC2 kinase activity in vitro. Wild-type cells (JK9-3da; mock) and wild-type (DS2; WT) or nip7-1 (DS3; nip7-1) cells
expressing AVO3-HA were grown in YPD at 30C. AVO3-HA was immunoprecipitated and subjected to a TORC2 kinase assay in vitro using recombinant YPK2
protein as a substrate. Also shown are Coomassie blue-stained total YPK2 protein and immunoblot of immunoprecipitated AVO3-HA.
See also Figure S1.subunit and assembled ribosomes (80S monosomes and
polysomes), whereas knockdown of ribosomal protein Rps16
(40S subunit) reduced the amounts of the 40S subunit and
assembled ribosomes (Figure S2C). We also observed that
knockdown of Rpl7 or Rps16 reduced the amounts of otherproteins in the corresponding ribosomal subunit (Figure 3A and
Figure S3A), consistent with the published finding that ribosomal
subunit assembly determines the level of ribosomal proteins
(Idol et al., 2007). Like knockdown of mNIP7, knockdown of
either Rpl7 or Rps16 decreased basal and insulin-stimulatedCell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc. 759
Figure 2. mNIP7 Is Required for mTORC2 Activity
In Vivo and In Vitro
(A) siRNA-mediated knockdown of mNIP7 inhibits
mTORC2 signaling. HeLa cells, 48 hr after transfection
with the indicated siRNA, were harvested (left) or serum
starved for 3 hr and then restimulated with insulin for the
indicated times before harvesting (right). Phosphorylation
and protein levels were determined by immunoblotting
with the appropriate antibodies, as indicated.
(B) Knockdown of mNIP7 inhibits mTORC2 kinase activity
toward Akt with no effect on mTORC2 integrity. rictor
immunoprecipitates were immunoblotted with the indi-
cated antibodies to determine mTORC2 integrity.
mTORC2 in vitro kinase assay was performed using
immunopurified mTORC2 (rictor) and recombinant,
kinase-dead Akt as a substrate.
See also Figure S2.phosphorylation of Akt (Ser473 and Thr450), FoxO3a (Thr32),
NDRG1 (Thr346), and rictor, with no effect on Erk or S6K phos-
phorylation (Figure 3A, Figure S2B, and Figure S3A). Finally,
we observed that Rpl7 knockdown reduced mTORC2 kinase
activity, as determined by an in vitro kinase assay with immuno-
purified mTORC2 and recombinant, kinase-dead Akt as a
substrate. Rpl7 knockdown had no effect on mTORC2 amount
or integrity, as determined by unaffected coimmunoprecipitation
of mTOR, mSIN1, or mLST8 with rictor (Figure 3B). Thus, assem-
bled ribosomes (not 60S or 40S ribosomal subunits alone) are
required for mTORC2 kinase activity and signaling. Furthermore,
the above findings suggest that mNIP7 controls mTORC2 via its
role in ribosome maturation.
mTORC2 promotes cell survival via phosphorylation and
activation of Akt, which in turn phosphorylates and inhibits
proapoptotic Bad (Brazil et al., 2004; Datta et al., 1997; Jacinto
et al., 2006; Yang et al., 2006). To investigate further the physio-
logical relevance of ribosome-mediated mTORC2 regulation, we
examined the effect of mNIP7, Rpl7, or Rps16 knockdown on
induction of apoptosis by etoposide or hydrogen peroxide
(H2O2). Both treatments induce cell death in an Akt-sensitive
manner (He et al., 2010; Kim et al., 2001; Wang et al., 2000).
Knockdown of mNIP7, Rpl7, or Rps16 enhanced the induction
of apoptosis by etoposide or hydrogen peroxide, as indicated
by an increase in caspase 3 and PARP cleavage and a decrease
in cell viability (Figure 4A and Figure S4). Knockdown of mSIN1
(mTORC2) similarly enhanced apoptosis. Knockdown of Bad760 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.blocked the proapoptotic effect of mSIN1,
mNIP7, Rpl7, or Rps16 knockdown (Figure 4B).
Thus, ribosomes appear to regulate mTORC2
signaling in a physiologically relevant manner.
Although ribosomal knockdown reduces
mTORC2 kinase activity and signaling without
affecting mTORC2 synthesis, is the process of
protein synthesis per se required for mTORC2
activation? To address this question, we exam-
ined whether the protein synthesis inhibitors
salubrinal, cycloheximide, anisomycin, or puro-
mycin acutely inhibit mTORC2 signaling. Salu-
brinal blocks translation initiation by selectiveinhibition of eIF2a dephosphorylation (Boyce et al., 2005; Cnop
et al., 2007) (Figure S3B). Cycloheximide, anisomycin, and puro-
mycin inhibit translation elongation. Unlike knockdown of
mNIP7, Rpl7, or Rps16, salubrinal, cycloheximide, anisomycin,
and puromycin had no effect on basal or insulin-stimulated Akt
Ser473 phosphorylation (Figures S3B–S3D and Figure S5C). All
drugs were used under conditions known to affect protein
synthesis in the expected manner, as determined by polysome
gradient analysis (Figures S3B–S3D and data not shown).
Thus, ribosomes mediate mTORC2 signaling independently of
protein synthesis.
Active mTORC2 Is Associated with the Ribosome
To investigate the molecular mechanism by which ribosomes
activate mTORC2 signaling, we examined by four unrelated
methods whether ribosomes and mTORC2 physically interact.
First, we determined whether mTORC2 coimmunoprecipitates
with ribosomal protein Rpl26. Endogenous Rpl26 coimmunopre-
cipitated with endogenous mTOR, rictor, mSIN1, and ribosomal
protein Rpl7 (Figure 5A), but not with raptor. This suggests that
mTORC2, but not mTORC1, associates with the ribosome.
Second, we determined whether mTORC2 copurifies with total
ribosomes isolated by sedimentation through a sucrose cushion
(see Experimental Procedures). mTOR and rictor, but not raptor,
cosedimented with Rpl26, Rpl7, and Rps16 (Figure 5B). Third,
although ribosomes activate mTORC2 independently of protein
synthesis, we also determined whether mTORC2 cosediments
Figure 3. Ribosomes Are Required for mTORC2
Activity and Signaling
(A) siRNA-mediated knockdown of Rpl7 inhibits mTORC2
signaling. HeLa cells, 24 hr after transfection with the
indicated siRNA, were harvested (left, basal activity) or
serum starved for 3 hr and then restimulated with insulin
for the indicated times before harvesting (right, insulin-
stimulated activity). Phosphorylation and protein levels
were determined by immunoblotting with the appropriate
antibodies, as indicated.
(B) Knockdown of Rpl7 inhibits mTORC2 kinase activity
toward Akt with no effect on mTORC2 integrity. rictor
immunoprecipitates were immunoblotted with the indi-
cated antibodies. mTORC2 in vitro kinase assay was
performed using immunopurified mTORC2 (rictor) and
recombinant, kinase-dead Akt as a substrate.
See also Figure S3.with polysomes in a sucrose gradient. Lysates were fractionated
in a sucrose gradient to separate polysomes from 80S, 60S, and
40S ribosomes. mTOR, rictor, andmSIN1 were found in both the
polysomal and ribosomal fractions, to the same extent as Rpl7,
Rpl26, and Rps16 (Figure S5A). Finally, we determined whether
mTORC2 copurifies with mRNA-bound ribosomes. mRNA-
bound ribosomes were purified by pull-down of poly(A) mRNA
with oligo(dT) cellulose (Figure S5B) (Ceci et al., 2003). In this
experiment, mTOR and rictor copurified with Rpl26, Rpl7, and
the 40S ribosomal protein RACK1. RNase A treatment of a lysate
before pull-down prevented isolation of any of the above
proteins (Figure S5B), confirming interaction of mTORC2 with
mRNA-bound ribosomes. The above data taken together
suggest that mTORC2 physically interacts with translating
(mRNA-bound) and nontranslating 80S ribosomes. An interac-
tion between mTORC2 and the 80S ribosome is also supported
by published mass spectrometry studies that identified several
large and small subunit ribosomal proteins in mTORC2 immuno-
precipitates (Pearce et al., 2007; Thedieck et al., 2007). We also
note that nonionic detergent was required during any of our four
above ribosome purifications to detect copurification of
mTORC2 and that protein synthesis inhibitors had no effect on
the interaction between mTORC2 and Rpl26 (Figure S5C).
To obtainmore insight into themTORC2-ribosome interaction,
we performed coimmunoprecipitation experiments after knock-
down of mTORC2 subunits or ribosomal proteins. First, the
amount of mTOR in Rpl26 immunoprecipitates from rictor or
mSIN1 knockdown cells was significantly reduced compared
to control cells (Figure S6A), suggesting that mTORC2 interactsCell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc. 761r
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twith the ribosome via rictor and/or mSIN1. We
could not distinguish a requirement specifically
for rictor or mSIN1 because knockdown of
either rictor or mSIN1 alone also results in loss
of the other. Second, knockdown of Rpl7 (60S
subunit) abolished the interaction between
mTORC2 and Rpl26, whereas knockdown of
Rps16 (40S subunit) only moderately decreased
the interaction between mTORC2 and Rpl26
(60S subunit) (Figure S6B). These resultssuggest that mTORC2 associates with the ribosome via ricto
and/or mSIN1 binding to the 60S subunit.
The above findings suggest that ribosomes bind and activate
mTORC2. To test this model further, we investigated whethe
ribosome-bound mTORC2 is indeed active. We performed an
mTORC2 kinase assay with ribosomes purified either by Rpl26
immunoprecipitation or by sedimentation through a sucrose
cushion,asdescribedabove. Inbothcases,a ribosome-associated
kinase phosphorylated Ser473 in recombinant, kinase-dead Ak
(Figure 5C). ThemTOR inhibitor PP242 (Feldman et al., 2009) abol-
ished the in vitro phosphorylation of Ser473 (Figure 5C), confirming
that the ribosome-associated Ser473 kinase was mTORC2. Thus
ribosome-associatedmTORC2 isactive.Furthermore,weanalyzed
whethermTORC2kinaseactivity is required formTORC2-ribosome
interaction. Treatment of HeLa cells with PP242 abolished Ser473
phosphorylation, as expected, but had no effect on mTORC2-
Rpl26 interaction (Figure S6D), suggesting that mTORC2 activity
is not required for mTORC2-ribosome association.
Insulin-PI3K Signaling Stimulates mTORC2-Ribosome
Association
We next investigated whether mTORC2 association with the
ribosome is regulated by insulin. Insulin treatment of serum-
starved cells significantly increased the amount of mTOR and
rictor that coimmunoprecipitated with Rpl26 (Figure 6A). Impor-
tantly, this stimulation of the interaction between mTORC2 and
Rpl26 correlated with phosphorylation of the mTORC2 targe
site Ser473 in endogenous Akt. Thus, insulin stimulates
mTORC2-ribosome association.
Figure 4. Ribosome or mTORC2 Knockdown Enhances Stress-Induced, Bad-Dependent Apoptosis
(A) siRNA-mediated knockdown of mSIN1, mNIP7, Rpl7, or Rps16 increases etoposide-induced apoptosis. HeLa cells were transfected with the various siRNAs
and then treated with 25 mM etoposide for the indicated times (top) or for 24 hr (bottom). Extracts were analyzed by immunoblotting to assess efficiency of siRNA
knockdown and induction of apoptosis with the indicated antibodies (top). Apoptosis was assessed by blotting for cleaved PARP (cPARP) and cleaved caspase 3
(cCaspase 3). Cells were fixed and stained with DAPI and cleaved PARP antibody to detect apoptotic cells (bottom).
(B) Bad is required for enhanced apoptosis in cells with knockdown of mSIN1, mNIP7, Rpl7, or Rps16. HeLa cells were transfected with the indicated siRNA and
then treated with 25 mM etoposide for 24 hr. Extracts were analyzed by immunoblotting to assess the induction of apoptosis with cleaved PARP antibody. The
efficiency of Bad knockdown is shown.
See also Figure S4.Insulin activates mTORC2 via PI3K (Frias et al., 2006; Garcı´a-
Martı´nez and Alessi, 2008; Yang et al., 2006). To investigate
whether PI3K signaling regulates mTORC2 association with
the ribosome, we examined whether the mTORC2-Rpl26 inter-
action was affected upon inhibition or hyperactivation of PI3K
signaling. Inhibition of PI3K strongly decreased mTORC2-
Rpl26 interaction, as determined by a reduction in the amount
of mTOR and rictor that coimmunoprecipitated with Rpl26 in762 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.lysates from cells treated with the PI3K inhibitor LY294002 (Fig-
ure 6B and Figure S6D). In contrast, hyperactivation of PI3K
signaling by knockdown of PTEN, a negative regulator of PI3K
signaling, increased the amount of mTOR and rictor in Rpl26
immunoprecipitates, compared to control cells (Figure 6C).
Again, the change in mTORC2-Rpl26 interaction upon PI3K inhi-
bition or hyperactivation was paralleled by a corresponding
change in phosphorylation of the mTORC2 target site Ser473
Figure 5. Active mTORC2 Is Associated with the
Ribosome
(A) Endogenous Rpl26 coimmunoprecipitates with
endogenous mTOR, rictor, and mSIN1. Rpl26 and mock
immunoprecipitations were performed with HeLa cell
extracts and analyzed by immunoblotting with the indi-
cated antibodies.
(B) mTORC2 associates with ribosomes. Ribosomes were
purified from HeLa cells by sedimentation through a
sucrose cushion. Ribosomes were probed with the indi-
cated antibodies (left) or were resedimented through a
sucrose gradient to monitor 40S, 60S, and 80S ribosomes
and polysomes. The absorbance profile of the sucrose
gradient was determined at 254nm (right).
(C) Ribosome-associated mTORC2 is active. mTORC2
kinase assays were performed with Rpl26 or mock
immunoprecipitates using recombinant, kinase-dead Akt
as a substrate and in the presence or absence of the
mTOR inhibitor PP242 (left). mTORC2 kinase assay was
performed with ribosomes purified as described in (B),
with recombinant, kinase-dead Akt as a substrate and in
the presence or absence of PP242 (right).
See also Figure S5.in endogenous Akt (Figures 6B and 6C). Taken together, the
above data suggest that insulin stimulates mTORC2-ribosome
association in a physiologically relevant manner via PI3K.
mTORC2-Ribosome Interaction Promotes Akt Signaling
in Cancer Cells
PI3K-dependent association of mTORC2 with the ribosome,
ribosome-mediated mTORC2 activation, and the physiologicalrelevance of mTORC2-ribosome interaction in promoting cell
survival prompted us to analyze mTORC2-ribosome association
in cancer cells with hyperactive PI3K signaling. First, we exam-
ined whether PTEN-deficient metastatic melanoma cells have
elevated mTORC2 activity. Approximately 60% of metastatic
melanomas have reduced PTEN expression and elevated Akt
phosphorylation (Robertson, 2005; Stahl et al., 2004). We
analyzed PTEN expression and Akt Ser473 phosphorylation inFigure 6. Insulin-PI3K Signaling Stimulates
mTORC2-Ribosome Association
(A) Insulin stimulates mTORC2-ribosome association.
HeLa cells were serum starved and then restimulated with
insulin for the indicated time. Rpl26 immunoprecipitates
(IP: Rpl26) and cell extracts (lysate) were immunoblotted
with the indicated antibodies.
(B) PI3K inhibition decreases mTORC2-ribosome associ-
ation. HeLa cells were treated with LY294002 (50 mM
final concentration) for 30 min before harvesting. Rpl26
immunoprecipitates and cells extracts (lysate) were im-
munoblotted with the indicated antibodies.
(C) siRNA-mediated knockdown of PTEN increases
mTORC2-ribosome association. HeLa cells were trans-
fected with the indicated siRNA and then harvested after
48 hr. Rpl26 immunoprecipitates and cell extracts (lysate)
were analyzed by immunoblotting with the indicated
antibodies.
See also Figure S6.
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Figure 7. mTORC2-Ribosome Interaction Pro-
motes Akt Signaling in Cancer Cells
(A) Akt Ser473 phosphorylation inversely correlates with
PTEN expression in human melanoma cells. Cell extracts
from six human melanoma cell lines were analyzed by
immunoblotting with indicated antibodies.
(B) PTEN-deficient cell lines exhibit increased mTORC2-
ribosome association. Ribosomes were purified from
PTEN-deficient (NA8 and ME67) and PTEN-positive
melanoma cell lines (Juso) by sedimentation through a
sucrose cushion. Ribosomes were probed with the indi-
cated antibodies.
(C) Knockdown of mSIN1 or Rpl7 induces apoptosis in
PTEN-deficient (NA8 andME67) melanoma cell lines. Cells
were transfected with the indicated siRNA and harvested
after 72 hr. Extracts were analyzed by immunoblotting to
check the efficiency of the knockdown and the induction
of apoptosis (PARP and caspase 3 cleavage) with the
indicated antibodies.
See also Figure S7.six human metastatic melanoma cell lines generated from
different patients (Certa et al., 2001; Deschodt-Lanckman
et al., 1990; Gervois et al., 1996). PTEN expression inversely
correlated with Akt Ser473 phosphorylation (Figure 7A). For
further study, we chose the two cell lines NA8 and ME67 with
low PTEN expression and high Akt Ser473 phosphorylation
(mTORC2 activity) and, as a control, the cell line Juso with the
opposite signaling profile. To examinemTORC2-ribosome asso-
ciation, ribosomes were isolated from the three cell lines and
probed for mTOR, rictor, and mSIN1. In all cases, the total yield
of ribosomes obtained by sedimentation through a sucrose
cushion was similar. However, the PTEN-deficient NA8 and
ME67 cells exhibited significantly increased levels of mTORC2
associated with the ribosomal fraction as compared to the
PTEN-positive Juso cells (Figure 7B), consistent with our PTEN
knockdown studies in HeLa cells described above (Figure 6C).
We also examined mTORC2-ribosome interaction in colon
cancer cells harboring an activating mutation in the PI3K gene
PIK3CA. The PIK3CA mutant cell lines HT29 and HCT116
exhibited both Akt Ser473 hyperphosphorylation (mTORC2
activity) and increased mTORC2-ribosome association as
compared to SW60 colon cells harboring an unaltered PIK3CA
gene (Figure S7A). Thus, mTORC2-ribosome interaction
correlates with mTORC2 activity in both melanoma and colon
cancer cells.
To investigate further the physiological relevance of mTORC2
activation via ribosome association, we examined the effect
of mSIN1 and Rpl7 knockdown on mTORC2 signaling and
cell survival in NA8, ME67, and Juso cells. Knockdown of
either mSIN1 or Rpl7 decreased Akt Ser473 phosphorylation764 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.(Figure 7C), supporting a role for ribosome-
dependent activation of mTORC2 in cancer.
Furthermore, knockdown of either mSIN1 or
Rpl7 enhanced apoptosis both in the presence
and absence of etoposide. Interestingly, the
increase in apoptosis was more pronounced in
the PTEN-deficient NA8 and ME67 cells thanin Juso cells, suggesting that NA8 and ME67 cells are more
‘‘addicted’’ to mTORC2 (Figure 7C and Figure S7B). The above
results taken together suggest that mTORC2-ribosome associa-
tion, mediating PI3K-mTORC2-Akt signaling and cell survival, is
functionally important in cancer cells.
DISCUSSION
We investigated the upstream regulation of TORC2. A genetic
screen in yeast and subsequent studies in mammalian cells
revealed that ribosomes are upstream of TORC2. In particular,
we found the following. First, the genetic screen in yeast revealed
that knocking down ribosome biogenesis inhibits TORC2 kinase
activity in vitro (Figure 1D) and TORC2 signaling in vivo (Figures
1B and 1C and Figure S1). Second, the ribosome is required for
mTORC2 activity in vitro (Figure 2B and Figure 3B) and mTORC2
signaling in vivo in mammalian cells (Figure 2A, Figure 3A, and
Figure S3A). Knockdown of ribosome maturation factor mNIP7
or ribosomal proteins (Rpl7 or Rps16) in mammalian cells
decreased mTORC2 kinase activity and mTORC2 signaling.
Third, the ribosome (translating or nontranslating) interacts
directly with mTORC2 (Figures 5 and Figure S5). mTORC2 cop-
urified with ribosomes isolated by four independent methods.
Furthermore, mTORC2 copurified with ribosomes isolated from
growing cells or cells treated with protein synthesis inhibitors.
Fourth, ribosome-bound mTORC2 is active (Figure 5C), and
ribosome-free mTORC2 is inactive in vitro (Figure 2B, Figure 3B,
and Figure S6B). Fifth, PI3K-dependent insulin signaling stimu-
lates binding of the ribosome to mTORC2 (Figure 6 and Fig-
ure S6D) with the same kinetics that it stimulates mTORC2
activation (Figure 6A). Finally, the mTORC2-ribosome interaction
correlates with mTORC2 activity in both melanoma and colon
cancer cells (Figure 7 and Figure S7). Melanoma and colon
cancer cells with high PI3K activity (due to loss of PTEN or an
activating mutation in the PI3K gene) exhibited both enhanced
mTORC2-ribosome interaction and increased mTORC2 activity.
Our findings suggest that the translating or nontranslating 80S
ribosome binds and activates mTORC2 in response to growth
factor-stimulated PI3K signaling (Figure S7C). TORC2-ribosome
association is a mechanism of TORC2 activation that is likely
conserved from unicellular yeast to human. The ribosome is
presumably a primordial activator of TORC2 onto which growth
factor signaling was grafted during the evolution of
multicellularity.
In a parallel and complementary study, Oh et al. also showed
that mTORC2 associates with the ribosome (Oh et al., 2010).
Furthermore, they showed that mTORC2 phosphorylates the
Akt turn motif cotranslationally and the Akt hydrophobic motif
posttranslationally. Thus, Oh et al. investigated the role of the
mTORC2-ribosome interaction in downstream signaling by
mTORC2. Our study addresses the separate issue of upstream
regulation of mTORC2. We show that an mTORC2-ribosome
interaction activates mTORC2, and this activation is indepen-
dent of translation. In other words, an mTORC2-ribosome
interaction activates mTORC2 regardless of whether mTORC2
is phosphorylating a substrate co- or posttranslationally. We
note that Oh et al. did not examine a requirement for the ribo-
some in posttranslational phosphorylation.
A connection between ribosomes and TOR signaling is well
established. TORC1 activates ribosome biogenesis and protein
synthesis and inhibits autophagy as key readouts in the control
of cell growth. Why should ribosomes control TORC2? Ribo-
some content determines growth capacity of the cell and
TORC2 regulates growth-related processes. Thus, regulation
of TORC2 by ribosomes ensures that TORC2 is not inappropri-
ately activated in cells that are unable to grow. The above also
implies that TORC1, via activation of ribosome biogenesis and
inhibition of autophagy-mediated ribosome turnover, indirectly
controls TORC2. Indeed, Sarbassov et al. (Sarbassov et al.,
2006) have shown that inhibition of mTORC1 by long-term rapa-
mycin treatment indirectly inhibits mTORC2. Our findings
suggest that the effect of rapamycin on mTORC2 is due, at least
in part, to a reduction in ribosome content. Interestingly, the liter-
ature also indicates that ribosomal defects induce apoptotic cell
death, although the underlying mechanism is not understood
(Warner and McIntosh, 2009). We find that ribosomal defects
inhibit mTORC2 and its downstream effector Akt, which in turn
leads to Bad-dependent apoptosis. Thus, our findings also
provide a mechanism for the induction of apoptosis by a ribo-
somal defect.
Our findings suggest that ribosomes bind and activate
mTORC2 directly. The fraction of total mTORC2 that associates
with ribosomes varies depending on the cell type and the growth
conditions. For example, under normal growth conditions,20%
of total rictor (mTORC2) was associated with ribosomes in HeLa
cells, whereas 30%–40% of rictor was associated with ribo-
somes in PTEN-deficient cells such as melanoma and PTEN
knockdown cells. Thus, ribosome association appears to bea major if not the sole mechanism of TORC2 activation. Consid-
eration of the fraction of total ribosomes that associate with
mTORC2 is also potentially informative. Given that ribosomes
are 100- to 1000-fold more abundant than signaling kinases
such as mTORC2, only a small fraction of total ribosomes bind
mTORC2. This excess of ribosomeswould require strong regula-
tion ofmTORC2-ribosome binding by upstreamPI3K signaling to
achieve physiologically relevant regulation of mTORC2. Alterna-
tively, TORC2 could be regulated by a specific subpopulation of
ribosomes. Previous studies have demonstrated that TORC2 is
associated with membranes, including the endoplasmic retic-
ulum (ER) and Golgi apparatus, and that mTORC2 isolated from
ER microsomes phosphorylates Akt Ser473 in vitro (Drenan
et al., 2004; Hresko and Mueckler, 2005; Liu and Zheng, 2007;
Schroder et al., 2007; Sturgill et al., 2008). These findings suggest
that TORC2 might associate specifically with membrane-bound
ribosomes. In support of this notion, we observed that mTORC2
copurifies with ribosomes only when the ribosomes are isolated
in the presence of detergent. Membrane-bound ribosomes con-
stitute10% of total ribosomes and include both translating and
nontranslating ribosomes (Seiser and Nicchitta, 2000). It is also
interesting to note that Komili et al. (Komili et al., 2007) have
proposed a ribosome code in which there is a specialization of
ribosomes for specific cellular process.
Our findings are consistent with other studies proposing the
ribosome as a kinase platform. The two kinases PKCbII and
Pim-1 are associated with the ribosome via RACK1 and
Rps19, respectively (Ceci et al., 2003; Chiocchetti et al., 2005;
Grosso et al., 2008b). Overall, the ribosome appears to be
a signaling platform for mTORC2 and other kinases. Further-
more, ribosomal proteins have been shown to modulate the
activity of NF-kB, p53, and c-Myc (Lindstro¨m, 2009).
PI3K-Akt signaling is upregulated and contributes to tumori-
genesis in 60% of advanced-stage melanomas (Stahl et al.,
2003, 2004). PTEN expression or Akt inhibition increases
sensitivity of melanoma cells to apoptosis-inducing agents and
prevents tumor development (Madhunapantula and Robertson,
2009; Stahl et al., 2004). Our data, with melanoma, cancer colon,
and HeLa cells, suggest that PI3K signaling promotes Akt
phosphorylation via stimulation of mTORC2-ribosome binding.
Furthermore, disruption of the mTORC2-ribosome supercom-
plex selectively induces apoptosis in PTEN-deficient melanoma
cells (Figure 7C). The extent to which cells of other cancers
require ribosome-dependent mTORC2 activation is unclear,
although we expect that other cancers driven by mutations
promoting PI3K signaling may also depend on mTORC2-ribo-
some association. Disrupting the mTORC2-ribosome interaction
may be a useful strategy in the treatment of melanomas, colon
carcinomas, and possibly other cancers.
Several findings suggest that upregulation of the protein
synthesis machinery contributes to the development of cancer
and other diseases (Ruggero and Pandolfi, 2003). Consistent
with our findings, a ribosomal protein deficiency inhibits Akt-
driven tumorigenesis (Hsieh et al., 2010). Furthermore, the myc
oncogene enhances ribosome biogenesis, and myc oncoge-
nicity in mice can be blocked by mutations in ribosomal protein
genes (Barna et al., 2008; Ruggero, 2009). Our findings and the
observation that mTORC2 is required for tumor progression inCell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc. 765
at least some cancers (Guertin et al., 2009; Gulhati et al., 2009;
Masri et al., 2007) suggest that myc and increased ribosomal
content may promote tumorigenicity via stimulation of mTORC2
and its downstream effector Akt.
Curiously, our genetic screen in yeast yielded 44 TORC2
mutants but only a single mutant (nip7-1) that was defective in
ribosome biogenesis. Why did we not obtain more mutants
that were defective in ribosomal maturation factors or ribosomal
proteins? First, ribosomal genes are duplicated in yeast, thereby
precluding identification of recessive, loss-of-function mutations
in these genes. Second, YPK2 is downstream of the ribosome in
activation of TORC2 but is not downstream of the ribosome in
mediating protein synthesis, precluding full suppression of a ribo-
some biogenesis defect by YPK2*. YPK2* only partly suppresses
the nip7-1 mutation and only at semipermissive temperature.
EXPERIMENTAL PROCEDURES
Detailed protocols for apoptosis assays and statistical analyses can be found
in the Extended Experimental Procedures.
Yeast Strains, Media, Kinase Assays, Actin Staining, and Antibodies
Yeast strains used in this study are listed in the Table S1. All strains are
isogenic derivatives of JK9-3da. Plasmids used in this study are described
in Table S2. Standard techniques and media were used for yeast manipulation
(Kamada et al., 2005; Loewith et al., 2002). Unless indicated otherwise, cells
were grown in rich YPD medium. YPK2 and TORC2 kinase assays were
performed as described previously (Casamayor et al., 1999; Kamada et al.,
2005; Loewith et al., 2002; Wullschleger et al., 2005). Rhodamine phalloidin
staining of polymerized actin was performed as described (Loewith et al.,
2002; Mulet et al., 2006). Immunoprecipitations were performed as described
previously (Loewith et al., 2002; Wullschleger et al., 2005).
Reverse Suppressor Screen
A wild-type strain (JK9-3da) was transformed with an URA3-based plasmid
overexpressing YPK2* (pYPK2*) (Figure 1A). Cells were randomlymutagenized
with 100 mM ethyl-methanesulfonate (EMS) (Sigma) for 15 min in SD-Ura
medium, washed, and then allowed to recover in SD-Ura medium without
mutagen for 2–4 hr. Cells were plated on solid SD-Ura or SD supplemented
with 5-FOA and incubated at 30C. The SD medium supplemented with
5-FOA counterselected againstURA3 such that only those cells that had spon-
taneously lost the URA3-based pYPK2* plasmid were able to form a colony.
Mutants that were unable to grow on SD 5-FOA (and hence in the absence
of YPK2*) were isolated from the master SD-Ura plate. 45,000 colonies
from mutagenized cells were screened, from which 45 mutants were isolated
and the corresponding mutations were identified. Mutated genes were iso-
lated by complementation with a LEU2 centromeric plasmid-based yeast
genomic library. Complementing members of the genomic library were
selected by growth on SD-Leu medium containing 5-FOA. Genomic inserts
of library-derived plasmids were identified by sequencing. Complementation
with subclones of isolated inserts identified the complementing ORF within
a given insert. Sequencing of the genomic copy of NIP7 and meiotic segrega-
tion studies confirmed that NIP7 was indeed the relevant mutant gene. nip7-1
was found to be temperature sensitive upon subsequent characterization. For
experiments at semipermissive temperature (30C), nip7-1 cells were grown in
YPD at permissive temperature (25C), diluted to OD600 = 0.1, and grown at
30C to approximately OD600 = 0.6–0.8. For experiments at the nonpermissive
temperature (37C), nip7-1mutant was grown in YPD at 25C and then shifted
to 37C for 6 hr.
Cell Culture, Immunoprecipitations, Immunoblotting,
and mTORC2 Kinase Assay
HeLa, melanoma cells, and colon cancer cells were cultured, transfected,
stimulated, and harvested as described previously (Jacinto et al., 2004;766 Cell 144, 757–768, March 4, 2011 ª2011 Elsevier Inc.Thedieck et al., 2007). In brief, cells were seeded and grown for 48 hr in
DMEM supplemented with 10% serum (basal conditions). Cells were starved
of serum for 3 hr before restimulation with 100 nM insulin (Sigma).
For mSIN1, mNIP7, Rpl7, Rps16, PTEN, or Bad knockdown, a pool of four
different synthetic siRNA or of the appropriate control siRNA (Dharmacon)
was used as described (Thedieck et al., 2007). All transfections were done
according to the manufacturer’s instructions (Lipofectamine, Invitrogen
transfection).
Protein extracts were prepared as previously described (Jacinto et al., 2004;
Thedieck et al., 2007), resolved on SDS-PAGE, and transferred to nitrocellu-
lose membranes (Protran, Whatman). Immunoprecipitation, immunoblotting,
and mTORC2 kinase assays were performed as previously described (Jacinto
et al., 2004; Thedieck et al., 2007).Polysome Profiles, Ribosome Purification, and Poly(A) mRNA
Pull-Down
Polysome analysis using sucrose gradients was performed as described previ-
ously (Grosso et al., 2008b; Idol et al., 2007). For ribosome purification by sedi-
mentation through a sucrose cushion, HeLa ormelanoma cells were washed in
PBS, trypsinized, and lysed in buffer A (50mMTris-HCl [pH 7.4], 100mMNaCl,
30 mMMgCl2, 0.3% CHAPS, 100 ug/ml cycloheximide, 40 U/ml RNase inhib-
itor, protease inhibitor cocktail, and 100 ug/ml cycloheximide). Whole-cell
extracts were clarified at 4C, 10 min at 15,000 3 g. Extracts were loaded
on a 30% sucrose cushion in 50 mM Tris-acetate (pH 7.5), 50 mM NH4Cl,
12 mMMgCl2, and 1 mMDTT and ultracentrifuged for 17 hr in a SW41Ti Beck-
man rotor at 39,000 rpm. For the mTORC2 kinase assay, the ribosomal pellet
was resuspended in mTORC2 kinase buffer (Jacinto et al., 2004; Thedieck
et al., 2007). Ribosome-sucrose gradient fractionation was performed as
previously described (Grosso et al., 2008a). For poly(A) pull-down, HeLa cells
were washed with PBS, trypsinized, and lysed in buffer A. Whole-cell extracts
were clarified at 4C, 10 min at 8000 3 g. Lysates corresponding to 5 3 107
cells were incubated with oligo(dT) cellulose (Invitrogen) for 1 hr at room
temperature. After incubation, the oligo(dT) cellulose was pelleted andwashed
five times with buffer A. The bound fraction was eluted with elution buffer
(100mMTris [pH 7.4], 500mMNaCl, 10mMEDTA, 1% sodium dodecyl sulfate
(SDS), and 5 mM DTT). Purified ribosome fractions and the bound and
unbound fractions after poly(A) pull-down were concentrated with Vivaspin
500 (Sartorius Stedim) and analyzed by immunoblotting with the indicated
antibodies.SUPPLEMENTAL INFORMATION
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